DK3205653T3 - Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf - Google Patents

Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK3205653T3
DK3205653T3 DK15849469.0T DK15849469T DK3205653T3 DK 3205653 T3 DK3205653 T3 DK 3205653T3 DK 15849469 T DK15849469 T DK 15849469T DK 3205653 T3 DK3205653 T3 DK 3205653T3
Authority
DK
Denmark
Prior art keywords
sulphate
manufacture
crystal form
jak inhibitors
jak
Prior art date
Application number
DK15849469.0T
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Xiaohui Gao
Yongjiang Chen
Lingjia Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Application granted granted Critical
Publication of DK3205653T3 publication Critical patent/DK3205653T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK15849469.0T 2014-10-09 2015-09-09 Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf DK3205653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410529863.8A CN105566327A (zh) 2014-10-09 2014-10-09 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
PCT/CN2015/089223 WO2016054959A1 (zh) 2014-10-09 2015-09-09 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
DK3205653T3 true DK3205653T3 (da) 2021-01-11

Family

ID=55652569

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15849469.0T DK3205653T3 (da) 2014-10-09 2015-09-09 Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf

Country Status (15)

Country Link
US (1) US10150770B2 (da)
EP (1) EP3205653B1 (da)
JP (1) JP6830888B2 (da)
KR (1) KR20170057441A (da)
CN (2) CN105566327A (da)
AU (1) AU2015330554B2 (da)
BR (1) BR112017005564A2 (da)
CA (1) CA2963581C (da)
DK (1) DK3205653T3 (da)
ES (1) ES2836100T3 (da)
HU (1) HUE052924T2 (da)
PT (1) PT3205653T (da)
RU (1) RU2704795C2 (da)
TW (1) TWI675839B (da)
WO (1) WO2016054959A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6851572B2 (ja) 2014-11-05 2021-03-31 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Jakキナーゼ阻害剤の硫酸水素塩の結晶形およびその製造方法
JP6875407B2 (ja) * 2016-02-19 2021-05-26 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
UA123709C2 (uk) * 2016-11-23 2021-05-19 Усі Форчун Фармасьютікал Ко., Лтд КРИСТАЛІЧНІ ТА СОЛЬОВІ ФОРМИ 7Н-ПІРОЛО[2,3-d]ПІРИМІДИНІВ І СПОСІБ ЇХ ОДЕРЖАННЯ
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種jak激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
EP4188333A1 (en) 2020-07-28 2023-06-07 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
WO2022108911A1 (en) 2020-11-17 2022-05-27 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
CN118043051A (zh) * 2021-08-12 2024-05-14 江苏恒瑞医药股份有限公司 用于治疗或预防抗宿主病的吡咯并六元杂芳物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301114A3 (en) * 2000-06-26 2004-11-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP2691395B1 (en) * 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
ES2682755T3 (es) * 2011-12-21 2018-09-21 Jiangsu Hengrui Medicine Co. Ltd. Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales
AU2014277506B2 (en) * 2013-06-07 2017-08-31 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor

Also Published As

Publication number Publication date
US20180237438A1 (en) 2018-08-23
PT3205653T (pt) 2020-12-15
CA2963581C (en) 2022-07-12
AU2015330554A1 (en) 2017-04-27
RU2017114689A3 (da) 2019-01-22
BR112017005564A2 (pt) 2017-12-12
ES2836100T3 (es) 2021-06-24
EP3205653A1 (en) 2017-08-16
EP3205653B1 (en) 2020-11-25
JP6830888B2 (ja) 2021-02-17
CN105980389B (zh) 2017-12-19
RU2017114689A (ru) 2018-11-14
TWI675839B (zh) 2019-11-01
RU2704795C2 (ru) 2019-10-31
KR20170057441A (ko) 2017-05-24
JP2017530146A (ja) 2017-10-12
AU2015330554B2 (en) 2020-01-02
TW201613931A (en) 2016-04-16
CA2963581A1 (en) 2016-04-14
HUE052924T2 (hu) 2021-06-28
WO2016054959A1 (zh) 2016-04-14
US10150770B2 (en) 2018-12-11
CN105566327A (zh) 2016-05-11
EP3205653A4 (en) 2018-06-20
CN105980389A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3145437T3 (da) Ortodontisk apparatur og fremgangsmåde til fremstilling af et ortodontisk apparatur
DK3426859T3 (da) Gipspanel, anvendelse af et sådant panel og fremgangsmåde til fremstilling af et sådant panel
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3205653T3 (da) Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3071215T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3067355T3 (da) Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
DK3151859T3 (da) Virkningsfuld og effektiv kontrol af serumphosphat til optimal knogledannelse
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3077513T3 (da) Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3258809T3 (da) Smykkeelement og fremgangsmåde til fremstilling heraf
DK3390422T3 (da) Krystalformer af lnt
DK3277742T3 (da) Fluorescerende siloxanelastomer, fremgangsmåde til fremstilling af denne og anvendelsen
DK3529236T3 (da) Krystalformer af eravacyclin
DK3452424T3 (da) Fremgangsmåde og anlæg til fremstilling af cement